V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10277006 | 10065511 | 1.6 | 75.4 | 03 | 2017-07-27 | 2018-01-05 | Trabectedin | 02 | N | ICON8B TRIAL | 101801543 |
| 10277622 | 10065513 | 1.8 | 49.4 | Adjuvant (A) | 2021-04-19 | 2021-04-29 | null | 02 | N | TEMOZOLOMIDE + RT | 100962482 |
| 10278046 | 10065514 | 0 | 121.5 | Palliative (P) | 2021-07-14 | 2022-04-07 | CYTARABINE + RITUXIMAB | 02 | N | FLUOROURACIL + MITOMYCIN | 100142657 |
| 10279463 | 10065515 | 1.64 | 49.8 | 03 | 2018-03-14 | 2018-03-20 | Bortezomib + MELPHALAN | 02 | N | VISMODEGIB | 100152051 |
| 10280266 | 10065516 | 1.63 | 106.6 | null | 2019-02-27 | 2019-02-27 | Rucaparib | 02 | null | AZACITIDINE + VENETOCLAX | 100528963 |
| 10280783 | 10065518 | 1.75 | 121.1 | 02 | 2017-04-24 | 2017-07-29 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | TRASTUZUMAB EMTANSINE | 100115113 |
| 10283968 | 10065520 | 1.87 | 75.65 | Palliative (P) | 2019-04-28 | 2019-05-29 | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 02 | N | AML18 TRIAL | 100620638 |
| 10284501 | 10065521 | 1.78 | null | Palliative (P) | 2022-03-26 | 2022-03-31 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE | 02 | N | DURVALUMAB | 101580750 |
| 10284652 | 10065522 | 0 | 69.5 | null | 2019-12-18 | 2020-02-14 | CHLORAMBUCIL + RITUXIMAB | 02 | null | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 100409135 |
| 10284728 | 10065523 | 1.65 | 67 | Palliative (P) | 2020-10-01 | 2020-10-01 | Capecitabine + Carboplatin + RT | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101658494 |
| 10285735 | 10065524 | 1.53 | 83.15 | null | 2019-12-17 | 2019-12-17 | LORLATINIB | 02 | null | CARBOPLATIN + FLUOROURACIL | 100919886 |
| 10289946 | 10065528 | 1.72 | 67.9 | null | 2018-01-29 | 2020-06-18 | R Chlorambucil | 02 | N | ERLOTINIB | 100434061 |
| 10292499 | 10065529 | 1.82 | 53.7 | Palliative (P) | 2018-11-29 | 2019-09-12 | ATEZOLIZUMAB + BEVACIZUMAB | null | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101851387 |
| 10292516 | 10065530 | 1.67 | 52.3 | Adjuvant (A) | 2016-04-21 | 2016-07-28 | AZACITIDINE + VENETOCLAX | 02 | N | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101556712 |
| 10293663 | 10065531 | 1.61 | 90.7 | Palliative (P) | 2019-03-03 | 2019-04-24 | BLEOMYCIN | 02 | N | PARTNER TRIAL | 101641490 |
| 10294472 | 10065532 | 1.81 | 66.7 | null | null | 2020-12-17 | OSIMERTINIB | 02 | null | ICON8B TRIAL | 101787456 |
| 10295481 | 10065533 | 1.6 | 83 | Palliative (P) | 2021-04-26 | 2021-05-10 | ANAGRELIDE | N | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 101825217 |
| 10296424 | 10065534 | 1.67 | 49.5 | null | 2021-10-17 | 2021-11-01 | BOSUTINIB | N | null | BLEOMYCIN | 100068559 |
| 10296487 | 10065535 | null | null | null | null | 2018-04-28 | ISATUXIMAB + POMALIDOMIDE | 02 | null | CISPLATIN + PEMETREXED | 100596748 |
| 10296794 | 10065536 | 1.86 | 78.7 | null | 2020-09-03 | 2020-09-03 | Bevacizumab + Olaparib | null | null | NERATINIB | 100794867 |
| 10297559 | 10065537 | 1.63 | 62.8 | null | 2019-03-19 | 2020-05-24 | null | N | null | CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 100394923 |
| 10298584 | 10065540 | 1.78 | 62.7 | Disease modification (D) | 2021-01-04 | 2022-04-11 | null | 01 | N | DURVALUMAB | 101166478 |
| 10299345 | 10065542 | 0 | 50.8 | null | 2022-01-28 | 2022-03-07 | ABEMACICLIB + FULVESTRANT | 02 | null | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 100047422 |
| 10303134 | 10065548 | 1.75 | 86.7 | null | 2018-02-27 | 2018-03-12 | Doxorubin 50mg/m2 | null | null | TOPOTECAN | 101768203 |
| 10306520 | 10065552 | 1.66 | 77.8 | null | null | 2021-03-25 | FLUOROURACIL + MITOMYCIN + RT | null | null | DURVALUMAB | 101684894 |
| 10308206 | 10065555 | null | null | 03 | 2018-11-25 | 2018-12-24 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | 02 | N | DACARBAZINE | 101841523 |
| 10309527 | 10065557 | 1.69 | 85.2 | null | 2019-10-10 | 2020-06-29 | null | 02 | null | BRENTUXIMAB | 100699982 |
| 10311978 | 10065559 | null | null | null | 2019-07-16 | 2019-07-22 | LEAM | N | null | NINTEDANIB | 100469448 |
| 10346358 | 10065576 | 1.85 | 77.2 | null | 2020-01-01 | 2020-01-01 | Trial Unspecified | 02 | null | GEFITINIB | 101808960 |
| 10346928 | 10065577 | 1.73 | 65 | Curative (C) | 2022-01-19 | 2022-01-26 | VISMODEGIB | 02 | N | BOSUTINIB | 101345310 |
| 10347171 | 10065579 | 1.55 | 0 | null | 2019-05-19 | 2019-05-21 | Irinotecan + Raltitrexed | 02 | N | ERLOTINIB | 101200589 |
| 10348373 | 10065583 | 0 | 80 | Curative (C) | 2020-10-13 | 2021-01-05 | FCR Oral - Cycle 1 | 02 | Y | OSIMERTINIB | 101246639 |
| 10348886 | 10065585 | 1.71 | 75.1 | null | 2021-10-17 | 2021-11-03 | OSIMERTINIB | 01 | null | CAPECITABINE + GEMCITABINE | 101262326 |
| 10349385 | 10065586 | 1.66 | 51.9 | Adjuvant (A) | 2020-08-08 | 2020-08-08 | null | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100377680 |
| 10349538 | 10065587 | 1.7 | 71.25 | null | 2020-05-21 | 2020-09-27 | null | N | null | LENALIDOMIDE + RITUXIMAB | 101623375 |
| 10358134 | 10065591 | 1.72 | 70.3 | null | 2019-11-23 | 2020-02-23 | null | 02 | null | METHOTREXATE INTRATHECAL | 101767308 |
| 10359844 | 10065594 | 1.81 | 53.7 | null | 2020-06-26 | 2020-07-02 | Mercaptopurine | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101704836 |
| 10360895 | 10065595 | 1.5 | 81.6 | Curative (C) | 2018-05-28 | 2018-08-01 | OSIMERTINIB | 02 | N | GEMCITABINE + NAB-PACLITAXEL | 101609114 |
| 10362044 | 10065597 | 1.67 | 85 | Palliative (P) | 2019-02-05 | 2019-02-05 | Binimetinib + Encorafenib | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101165589 |
| 10366416 | 10065599 | 1.53 | 0 | Palliative (P) | 2019-10-31 | 2020-04-26 | TOPOTECAN | 02 | N | VISMODEGIB | 101417409 |
| 10377518 | 10065605 | 1.77 | 76.4 | null | 2018-05-21 | 2018-07-09 | Alemtuzumab | 02 | null | CAPECITABINE + CISPLATIN | 100064549 |
| 10381938 | 10065607 | 0 | 98.35 | null | 2018-08-02 | 2019-02-26 | PARTNER Trial | 99 | null | FLUOROURACIL + OXALIPLATIN + PANITUMUMAB | 101748891 |
| 10388861 | 10065612 | 0 | 0 | Disease modification (D) | 2018-09-28 | 2019-01-25 | EC | 02 | N | CYTARABINE | 101616462 |
| 10389528 | 10065613 | 1.57 | 76 | Palliative (P) | 2015-11-12 | 2017-09-26 | null | 02 | N | FLUOROURACIL + MITOMYCIN | 101248608 |
| 10391097 | 10065616 | 1.6 | 89.2 | null | 2020-02-27 | 2020-02-27 | TRANSPLANT CYCLOPHOSPHAMIDE + FLUDARABINE + TREOSULFAN | 2 | null | CAPECITABINE + MITOMYCIN | 101266589 |
| 10395753 | 10065621 | null | null | null | 2020-02-25 | 2020-02-25 | FLAIR trial | 01 | null | LENALIDOMIDE + RITUXIMAB | 101611413 |
| 10406530 | 10065628 | null | null | 03 | 2018-07-09 | 2018-07-09 | Alemtuzumab(INTRAVENOUS) | 02 | N | CYTARABINE | 100252882 |
| 10407616 | 10065630 | 1.81 | 99.4 | 03 | 2020-01-17 | 2020-01-20 | null | null | N | ICON8B TRIAL | 100748066 |
| 10407907 | 10065631 | 1.75 | 73 | Neo-adjuvant (N) | 2019-08-18 | 2019-08-19 | DTPACE | 02 | N | CHLORAMBUCIL + ETOPOSIDE | 100734335 |
| 10410017 | 10065632 | 1.77 | 67.8 | 03 | 2019-08-26 | 2020-09-02 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | VISMODEGIB | 100826149 |